“…The difference between the groups was mainly driven by a reduced risk of major bleeding in the ticagrelor monotherapy group (0.2% vs. 1.6%, HR, 0.13; 95% CI, 0.04–0.44; p=0.001). 62) The Comparison Between P2Y 12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES (SMART-CHOICE) trial compared clinical benefits of aspirin plus a P2Y 12 receptor inhibitor for 3 months and thereafter P2Y 12 receptor inhibitor alone or DAPT for 12 months in Korean patients treated with drug-eluting stent (DES) (n=2,993, 58.2% of patients with ACS). 63) There were no significant differences in all-cause death (1.4% vs. 1.2%, HR, 1.18; 95% CI, 0.63–2.21; p=0.61), MI (0.8% vs. 1.2%, HR, 0.66; 95% CI, 0.31–1.40, p=0.28), or stroke (0.8% vs. 0.3%, HR, 2.23; 95% CI, 0.78–6.43, p=0.14) between the two groups.…”